Long-term Survival Data from Longeveron's ELPIS 1 Trial
Extended Follow Up Data Show Continued, Transplant Free Survival of All Patients Results Support Continued Investigation of Lomecel-BTM As Adjunct to...
Stay updated with breaking news from Sunjay Kaushal. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Extended Follow Up Data Show Continued, Transplant Free Survival of All Patients Results Support Continued Investigation of Lomecel-BTM As Adjunct to...
Advancements in healthcare and medicine have helped contribute to the reduction in child mortality rates, plummeting from 185 per 1,000 births a century ago to just 7 per 1,000 births in 2020. However, some serious pediatric conditions continue to pose a threat.
MIAMI, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs,
19.01.2023 - - Full results published in European Heart Journal Open - - Study met primary safety endpoint - - All patients alive, transplant-free, and maintained expected rate of growth one year after treatment - - Data supports ongoing clinical ... Seite 1
Back in-person, The Children's Heart Foundation led the 2022 Chicago Congenital Heart Walk on June 11 at the Lincoln Park Rowing Lagoon, next to Lincoln Park Zoo. This year, the Chicago walk raised more than $167,000 for heart research, surpassing its initial goal of $110,500.